Multiple Myeloma
Latest Articles
(Celgene) Feb 24, 2017 - Oral REVLIMID® is the first and only medicine licensed in Europe for use as post-autologous stem cell transplantation maintenance therapy in multiple myeloma; the new indication expands the availability of REVLIMID® across the disease continuum of multiple myeloma.
Read Article
(Morningstar) Feb 24, 2017 - CHMP issued positive opinion for DARZALEX for relapsed or refractory multiple myeloma; final decision from European Commission expected in the coming months; opinion based on data from two Phase III studies, CASTOR and POLLUX.
Read Article
More Articles
February 24, 2017
February 23, 2017
February 23, 2017
February 22, 2017
February 13, 2017
December 09, 2016
December 07, 2016
December 07, 2016
View More
News Commentary
Editor Image
18 Apr, 2016 | by William McGivney, PhD
ICER: A Threat to OS in the US ...
View Comment
View More
OBR Green
There are no Multiple Myeloma OBR Green articles.
OBR Blog
This year's ASH Annual Meeting will be chock-full of interesting, informative, and clinically useful presentations,... Read more
November 22, 2016